News
Form Bio and Weill Cornell Medicine Announces Strategic Collaboration to Advance Gene Editing Therapy for Alzheimer's Disease
Form Bio partnered with Weill Cornell Medicine to apply AI-driven vector design and gene editing for developing therapies that lower Alzheimer’s disease risk in patients with high-risk genetic variants, marking the first phase of a multi-step clinical translation program.
Liverpool, CyanoCapture Team Up for Bionanotech Breakthrough
The University of Liverpool and CyanoCapture Ltd partnered to develop carboxysome-based targeted drug delivery systems by combining cyanobacteria engineering, peptide expression, and CRISPR-based molecular tools with scalable biomanufacturing to create protein nanocage platforms for biopharmaceutical applications.
Fork & Good Acquires Orbillion to Take Cultivated Red Meat Platform Global
Fork & Good acquired Orbillion Bio to combine their cultivated meat operations and accelerate the global commercialization of their red meat protein platform.
Samsung Life Science Fund Invests in Arbor Biotechnologies to Develop Next-Generation Genetic Medicines
Samsung Ventures invested in Arbor Biotechnologies to support the development of next-generation in vivo gene editing therapies for genetic diseases of the liver and central nervous system, reinforcing Samsung’s commitment to advancing biopharmaceutical technologies with meaningful clinical impact.
Valthos Secures $30 Million to Develop AI-Powered Biodefense Platform Against Biological Threats
Valthos raised $30 million in seed funding from OpenAI Startup Fund, Lux Capital, and Founders Fund to develop AI-driven biodefense systems that can identify biological sequences and design medical countermeasures in real time
ICHORtec and Johns Hopkins University Expand Collaboration to Enhance CRISPR Gene Editing Specificity Using Quantum FMB® Technology
ICHORtec expanded its collaboration with Johns Hopkins University to use its Quantum FMB® technology for improving the precision of CRISPR guide RNA design and evaluation, aiming to reduce off-target effects and enhance the accuracy of gene editing therapies.
iOrganBio Emerges from Stealth with $2M and Launches CellForge™, the First AI-Powered Cell Manufacturing Platform
iOrganBio emerged from stealth with $2 million in funding led by First Star Ventures to launch CellForge™, an AI-powered cell manufacturing platform that integrates predictive modeling and high-throughput control to engineer human cells and organoids for applications in drug discovery, regenerative medicine, and cell therapy.
Vow Introduces Australia’s First Home-Ready Cultured Meat Product: Cultured Quail Sprad
Vow, through its Forged brand, launched Australia’s first home-consumable cultured meat product, a Smoked Cultured Quail Spread, making a limited batch available for purchase and marking a milestone in bringing cultivated meat to home kitchens.
Industry leaders use Knowledge Hub to explore 900+ Synthetic Biology news
Gain unparalleled insights, and drive your innovation forward.
Let’s shape tomorrow, today!